
|Videos|June 7, 2019 (Updated: December 19, 2020)
Diving Deeper Into the Relationship Between Inflammation and Depression in Lung Cancer
Author(s)Daniel C. McFarland, DO
In this video, Dr. McFarland of Memorial Sloan-Kettering Cancer Center spoke with Cancer Network at ASCO 2019 about depression in lung cancer and dopamine as potential therapy.
Advertisement
Cancer Network spoke with Daniel C. McFarland, DO, medical oncologist at Memorial Sloan-Kettering Cancer Center, at the 2019 American Society of Clinical Oncology (ASCO) Annual Meeting about the relationship between inflammation and depression in lung cancer patients and the potential efficacy of dopamine in treating depression.
Newsletter
Stay up to date on recent advances in the multidisciplinary approach to cancer.
Advertisement
Advertisement
Advertisement
Trending on CancerNetwork
1
Neoadjuvant Chemo/Nivolumab Yields Deep Responses in Borderline-Resectable PDAC Subset
2
FDA Approves Acalabrutinib Combo in Frontline CLL/SLL
3
ASCO Issues Updated Guideline for Stage IV NSCLC Therapy
4
FDA Accepts NDA for Giredestrant/Everolimus in ESR1-Mutated Breast Cancer
5












































